Cowen Upgrades Merrimack Pharmaceuticals (MACK) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MACK Hot Sheet
Price: $15.13 --0%
Rating Summary:
5 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
5 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Cowen upgraded Merrimack Pharmaceuticals (NASDAQ: MACK) from Market Perform to Outperform.
For an analyst ratings summary and ratings history on Merrimack Pharmaceuticals click here. For more ratings news on Merrimack Pharmaceuticals click here.
Shares of Merrimack Pharmaceuticals closed at $4.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Upgrades Wajax Corp (WJX:CN) (WJXFF) to Buy
- Kotak Upgrades Niva Bupa Health Insurance (NIVABUPA:IN) to Buy (1)
- UBS Upgrades Cosan SA (CSAN3:BZ) (CSAN) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
